Medical News

RSS

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million.

29 Nov 2010

First Edition: November 29, 2010

Today's headlines include advance coverage of Congress' lame duck session, as well as news about strategies surrounding deficit-reduction efforts and how they might impact health care costs.

29 Nov 2010

Teleflex to sell Telair's Actuation business to TransDigm

Teleflex Incorporated, a leading global provider of medical technology products, today announced that it has entered into a definitive agreement to sell the Actuation business of its subsidiary Telair International Incorporated to TransDigm Group, Incorporated (NYSE: TDG) for approximately $94 million. The transaction is subject to receipt of Hart-Scott-Rodino approval and other customary closing conditions and is expected to close by the end of 2010.

29 Nov 2010

Life Technologies launches Qubit 2.0 Fluorometer for molecular biology research

Life Technologies Corporation, a provider of innovative life science solutions, today announced the launch of its next-generation Qubit® 2.0 Fluorometer specifically for molecular biology researchers who work with precious samples and perform applications that require a large financial or time investment. The new system quantitates DNA, RNA and protein with accuracy, sensitivity, speed and ease-of-use.

29 Nov 2010

DePuy Spine, Lanx, Medtronic, Zimmer Spine and Codman support NREF's post-residency clinical fellowships

The NREF has reached agreements with Medtronic, Lanx and Zimmer Spine to provide funding to the NREF in support of the Foundation's post-residency clinical fellowship grant program. The NREF is pleased to report that it has renewed its agreements with Codman & Shurtleff, Inc. and DePuy Spine, Inc., who supported the inaugural year of the fellowship program in 2010.

29 Nov 2010

Weight Watchers introduces PointsPlus weight loss program in the U.S.

The new era of Weight Watchers is here. Today Weight Watchers, the world-renowned leader in weight management, has announced it is introducing in the United States a successor to its popular POINTS weight loss system–the new PointsPlus program.

29 Nov 2010

Toshiba to showcase episode-based care solutions at RSNA annual meeting

Containing costs while delivering high-quality, effective care is a directive of healthcare reform. With episode-based care as part of the reform mandate, many healthcare providers are uncertain about its effect on both patient outcomes and their bottom-line. Toshiba America Medical Systems, Inc. is partnering with leading healthcare providers to develop solutions to address episode-based care by effectively utilizing patient-focused imaging technology and a multidisciplinary collaborative approach to treatment.

29 Nov 2010

Ziehm Imaging launches SmartVascular software solution for vascular surgery

Ziehm Imaging's intuitive SmartVascular software considerably simplifies imaging in vascular surgery. It introduces an entirely new workflow for fast results. This solution raises efficiency levels, eliminates interim C-arm operating steps and automates the imaging processes. SmartVascular is compatible with all Ziehm Vision C-arms and tailored to vascular procedures.

29 Nov 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

AMAG updates product label of Feraheme Injection

AMAG Pharmaceuticals, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) regarding an update to the product label for Feraheme (ferumoxytol) Injection for intravenous (IV) use.

29 Nov 2010

New 'canSAR' cancer drug discovery database launched

A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from 'bench to bedside'.

29 Nov 2010

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces a successful meeting with the US Food and Drug Administration (FDA) to discuss the Company's clinical development of its Aganocide compound NVC-422, intended for use in the treatment of impetigo.

29 Nov 2010

QOI and Quantel enter co-promotion agreement for Activis PDT Lasers

QLT Inc. today announced that its wholly-owned U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"), and Quantel Medical and its distributor, Quantel USA, Inc., have entered into a co-promotion agreement for the sale of Activis PDT Lasers used to activate Visudyne® during photodynamic therapy of primarily classic lesions in wet age-related macular degeneration (AMD). The lasers are manufactured by Quantel Medical and sold by Quantel USA, Inc. and will be promoted by both Quantel USA, Inc. and QOI's sales force to the retina community in the United States.

29 Nov 2010

Toshiba announces multi-center trial to evaluate Time-SLIP Renal MR Angiography

Non-contrast MR angiography provides clear, high-quality images and can be used as an effective tool for diagnosing renal artery stenosis. To illustrate non-contrast MRA's ability as a diagnostic tool for renal artery stenosis, Toshiba has announced a multi-center trial to establish the clinical value of non-contrast Renal MRA using Time-SLIP.

29 Nov 2010

NDSsi launches new DOME S10 diagnostic imaging display for mammography screening at RSNA 2010

A highly advanced 10MP diagnostic imaging display capable of showing two 5MP images for back-to-back chest wall reads has been launched by medical technology leader NDS Surgical Imaging (NDSsi). The new 30-inch widescreen Dome S10 supports 10-bit and 8-bit grayscale image data through industry standard interfaces, eliminating the need for proprietary libraries. Featuring non-reflective glass for higher-clarity viewing, and state-of-the-art 4096 x 2560 resolution, the S10 has raised the bar in optical performance in mammography screening.

29 Nov 2010

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

Accentia Biopharmaceuticals, Inc. today announced a strategic agreement with Baxter Healthcare Corporation to provide Accentia with the exclusive, worldwide right to purchase Baxter's cyclophosphamide, which is marketed under the brand name Cytoxan, for the treatment of designated autoimmune diseases including multiple sclerosis.

29 Nov 2010

Depressed and suicidal individuals linked to low levels of stress hormone cortisol

Depressed and suicidal individuals have low levels of the stress hormone cortisol in their blood and saliva. They also have substances in their spinal fluid that suggest there is increased inflammation in the brain. These findings could help to develop new methods for diagnosing and treating suicidal patients.

29 Nov 2010

Tongjitang files going-private statement on Schedule 13E-3 with SEC

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it has filed a going-private transaction statement on Schedule 13E-3 with the United States Securities and Exchange Commission

29 Nov 2010

Baylor Health Care System receives $20 million to benefit transplantation initiatives

Baylor Health Care System Foundation announces that Annette C. and Harold C. Simmons have pledged $20 million to benefit transplantation initiatives within Baylor Health Care System. In recognition of this transformational gift, Baylor will rename the institute the Annette C. and Harold C. Simmons Transplant Institute.

29 Nov 2010